Hokusai-VTE study suggests certain sub-groups of venous thromboembolism patients may need review ( European Society of Cardiology ) In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin, according to the results of the Hokusai-VTE trial.
Sept. 1, 2013 - EurekAlert!
Positive Results for New Anticoagulant From Daiichi Sankyo A new entrant in the growing oral anticoagulant field shows promise for the treatment of venous thromboembolism (VTE) and pulmonary embolism (PE). The drug, edoxaban, is a new, once-daily Factor Xa inhibitor with a rapid onset of action that is under development by Daiichi Sankyo. Results of the Hokusai-VTE trial were presented at the European Society of Cardiology meeting in Amsterdam and ...
Sept. 1, 2013 - Forbes